MIT professor Andrew Lo (Credit: J.T. MacMillan Photography at Endpoints #BIO22)
July 18, 2022 11:27 AM EDTUpdated 01:47 PM
Deals
Bioregnum

Black­Rock joins An­drew Lo's risk analy­sis firm to search for odds-on biotech bets in tur­bu­lent times

MIT fi­nance pro­fes­sor An­drew Lo has more in­sid­er con­nec­tions than just about any oth­er aca­d­e­m­ic play­er you’ll find in any in­dus­try. And to­day, if you …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times